FDA Approves Vyvgart (efgartigimod alfa-fcab) for the Treatment of Generalized Myasthenia Gravis

Breda, the Netherlands—Dec. 17, 2021 - argenx SE (Euronext& Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that the U.S. Food and...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news